HUP0004169A3 - Insoluble insulin compositions and process for production thereof - Google Patents
Insoluble insulin compositions and process for production thereofInfo
- Publication number
- HUP0004169A3 HUP0004169A3 HU0004169A HUP0004169A HUP0004169A3 HU P0004169 A3 HUP0004169 A3 HU P0004169A3 HU 0004169 A HU0004169 A HU 0004169A HU P0004169 A HUP0004169 A HU P0004169A HU P0004169 A3 HUP0004169 A3 HU P0004169A3
- Authority
- HU
- Hungary
- Prior art keywords
- production
- insulin compositions
- insoluble insulin
- insoluble
- compositions
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6310497P | 1997-10-24 | 1997-10-24 | |
US8893098P | 1998-06-11 | 1998-06-11 | |
PCT/US1998/022434 WO1999021578A1 (en) | 1997-10-24 | 1998-10-22 | Insoluble insulin compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0004169A2 HUP0004169A2 (hu) | 2001-05-28 |
HUP0004169A3 true HUP0004169A3 (en) | 2001-06-28 |
Family
ID=26743043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0004169A HUP0004169A3 (en) | 1997-10-24 | 1998-10-22 | Insoluble insulin compositions and process for production thereof |
Country Status (21)
Country | Link |
---|---|
US (3) | US6268335B1 (hu) |
EP (1) | EP1039920A4 (hu) |
JP (2) | JP2001521004A (hu) |
KR (1) | KR20010024556A (hu) |
CN (1) | CN1276731A (hu) |
AR (1) | AR020047A1 (hu) |
AU (2) | AU1111799A (hu) |
BR (1) | BR9813111A (hu) |
CA (2) | CA2306877A1 (hu) |
CO (1) | CO4970769A1 (hu) |
EA (1) | EA200000453A1 (hu) |
HR (1) | HRP20000236A2 (hu) |
HU (1) | HUP0004169A3 (hu) |
ID (1) | ID24890A (hu) |
IL (1) | IL134901A0 (hu) |
NO (1) | NO20002038L (hu) |
PE (1) | PE123799A1 (hu) |
PL (1) | PL340255A1 (hu) |
SV (1) | SV1998000125A (hu) |
TR (1) | TR200001050T2 (hu) |
WO (2) | WO1999021573A1 (hu) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
CO4970787A1 (es) * | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
US7169889B1 (en) * | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
CN1406131A (zh) * | 2000-12-25 | 2003-03-26 | 株式会社资生堂 | 活化交感神经的香料组合物 |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US20020155614A1 (en) * | 2001-02-21 | 2002-10-24 | Tomlinson Andrew J. | Peptide esterification |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
WO2003020201A2 (en) * | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
US7030082B2 (en) * | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
US7166571B2 (en) * | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US6913903B2 (en) * | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
EP1429731B1 (en) * | 2001-09-19 | 2007-01-03 | Elan Pharma International Limited | Nanoparticulate insulin formulations |
WO2003053460A1 (en) * | 2001-12-19 | 2003-07-03 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
SK2432004A3 (sk) * | 2001-12-20 | 2005-04-01 | Eli Lilly And Company | Inzulínová zlúčenina s protrahovaným účinkom |
US20040038864A1 (en) * | 2002-06-27 | 2004-02-26 | Per Balschmidt | Use of dimethyl sulfone as isotonicity agent |
EP1605967A1 (en) * | 2003-03-13 | 2005-12-21 | Novo Nordisk A/S | Novel nph insulin preparations |
US20060258561A1 (en) * | 2003-03-13 | 2006-11-16 | Novo Nordisk A/S | Novel NPH insulin preparations |
US20050054818A1 (en) * | 2003-07-02 | 2005-03-10 | Brader Mark Laurence | Crystalline compositions for controlling blood glucose |
EP2085406A1 (en) * | 2003-07-25 | 2009-08-05 | ConjuChem Biotechnologies Inc. | Long lasting insulin derivatives and methods thereof |
MXPA06001283A (es) | 2003-08-05 | 2006-04-11 | Novo Nordisk As | Derivados de insulina novedosos. |
JP5697831B2 (ja) | 2003-12-03 | 2015-04-08 | ノヴォ ノルディスク アー/エス | 単鎖インシュリン |
EP2626368B1 (en) * | 2004-07-19 | 2016-12-21 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
CN101060856B (zh) | 2004-11-22 | 2011-01-19 | 诺和诺德公司 | 可溶、稳定的含胰岛素制剂 |
EP1679065A1 (en) * | 2005-01-07 | 2006-07-12 | OctoPlus Sciences B.V. | Controlled release compositions for interferon based on PEGT/PBT block copolymers |
EP1863840A1 (en) * | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Pegylated single-chain insulin |
WO2007074133A2 (en) | 2005-12-28 | 2007-07-05 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
WO2007081824A2 (en) * | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Fibrillation resistant proteins |
WO2007121318A2 (en) * | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
JP2009536670A (ja) * | 2006-05-10 | 2009-10-15 | スミスクライン・ビーチャム・コーポレイション | 化合物の細胞浸透性を増加させるための組成物および方法 |
WO2007135118A1 (en) * | 2006-05-24 | 2007-11-29 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations |
CN101573133B (zh) | 2006-07-31 | 2014-08-27 | 诺沃-诺迪斯克有限公司 | Peg化延长的胰岛素 |
EP2404934A1 (en) | 2006-09-22 | 2012-01-11 | Novo Nordisk A/S | Protease resistant insulin analogues |
EP2074140B8 (en) * | 2006-10-04 | 2015-10-28 | Case Western Reserve University | Fibrillation-resistant insulin and insulin analogues |
WO2008132224A2 (en) | 2007-04-30 | 2008-11-06 | Novo Nordisk A/S | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
ES2744384T3 (es) | 2007-06-13 | 2020-02-24 | Novo Nordisk As | Formulación farmacéutica que comprende un derivado de insulina |
ES2548304T3 (es) * | 2007-08-15 | 2015-10-15 | Novo Nordisk A/S | Análogos de la insulina que contienen una fracción acilo y alquilenglicol |
RU2453332C2 (ru) | 2007-10-16 | 2012-06-20 | Байокон Лимитид | Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц |
DE102008003566A1 (de) * | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
EP2229406B1 (de) * | 2008-01-09 | 2015-04-22 | Sanofi-Aventis Deutschland GmbH | Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil |
EP2229407B1 (de) | 2008-01-09 | 2016-11-16 | Sanofi-Aventis Deutschland GmbH | Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil |
WO2009112583A2 (en) | 2008-03-14 | 2009-09-17 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
AU2009226910B2 (en) | 2008-03-18 | 2014-02-06 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
US8993516B2 (en) * | 2008-04-14 | 2015-03-31 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
BRPI0911571A2 (pt) * | 2008-04-22 | 2018-04-03 | Univ Case Western Reserve | método para tratar um mamífero, análogo de insulina, ácido nucléico e célula hospedeira |
KR20120129875A (ko) | 2008-07-31 | 2012-11-28 | 케이스 웨스턴 리저브 유니버시티 | 염소화 아미노산을 갖는 인슐린 유사체 |
US9200053B2 (en) | 2008-07-31 | 2015-12-01 | Case Western Reserve University | Insulin analogues containing penta-fluoro-Phenylalanine at position B24 |
KR101939557B1 (ko) | 2008-10-17 | 2019-01-17 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린과 glp-1 효능제의 병용물 |
AU2009309623B9 (en) | 2008-10-30 | 2014-10-02 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
JP2012516340A (ja) | 2009-01-28 | 2012-07-19 | スマートセルズ・インコーポレイテツド | 合成コンジュゲートおよびその使用 |
CN105753965A (zh) | 2009-01-28 | 2016-07-13 | 斯马特塞尔斯公司 | 用于受控药物递送的基于缀合物的系统 |
WO2011034629A1 (en) * | 2009-02-05 | 2011-03-24 | Abbott Diabetes Care Inc. | Devices and methods for metering insoluble active agent particles |
EP2408808A4 (en) | 2009-03-20 | 2015-05-06 | Smartcells Inc | TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE |
WO2011003820A1 (de) * | 2009-07-06 | 2011-01-13 | Sanofi-Aventis Deutschland Gmbh | Hitze- und schüttelstabile insulinzubereitungen |
TW201113032A (en) * | 2009-07-06 | 2011-04-16 | Sanofi Aventis Deutschland | Slow-acting insulin preparations |
US8399407B2 (en) * | 2009-09-17 | 2013-03-19 | Case Western Reserve University | Non-standard insulin analogues |
CN107308442B (zh) | 2009-11-13 | 2022-10-18 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂、胰岛素和甲硫氨酸的药物组合物 |
PT3345593T (pt) | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina |
AU2010323117B2 (en) | 2009-11-25 | 2015-09-03 | Capsugel Belgium Nv | Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion |
MY189079A (en) | 2009-12-11 | 2022-01-25 | Univ Case Western Reserve | Insulin analogues with chlorinated amino acids |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
US8853155B2 (en) | 2010-06-23 | 2014-10-07 | Novo Nordisk A/S | Insulin derivatives containing additional disulfide bonds |
LT2611458T (lt) | 2010-08-30 | 2016-12-27 | Sanofi-Aventis Deutschland Gmbh | Ave0010 panaudojimas gaminant vaistą, skirtą 2 tipo cukrinio diabeto gydymui |
RU2013123515A (ru) | 2010-10-27 | 2014-12-10 | Ново Нордиск А/С | Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
WO2012171994A1 (en) | 2011-06-15 | 2012-12-20 | Novo Nordisk A/S | Multi substituted insulins |
MX370264B (es) | 2011-08-29 | 2019-12-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2. |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
AU2013247047A1 (en) | 2012-04-11 | 2014-10-23 | Novo Nordisk A/S | Insulin formulations |
US9707276B2 (en) | 2012-12-03 | 2017-07-18 | Merck Sharp & Dohme Corp. | O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues |
TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
UA117480C2 (uk) | 2013-04-03 | 2018-08-10 | Санофі | Лікування цукрового діабету за допомогою складу інсуліну тривалої дії |
JP2016519127A (ja) | 2013-04-30 | 2016-06-30 | ノヴォ ノルディスク アー/エス | 新規投与レジメン |
JP6499184B2 (ja) | 2013-10-07 | 2019-04-10 | ノヴォ ノルディスク アー/エス | インスリン類似体の新規な誘導体 |
JP6735674B2 (ja) * | 2014-01-09 | 2020-08-05 | サノフイSanofi | インスリンアスパルトの安定化された医薬製剤 |
BR112016013832A2 (pt) | 2014-01-09 | 2017-08-08 | Sanofi Sa | Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico |
EP3091995B1 (en) | 2014-01-09 | 2024-03-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
US10195254B2 (en) * | 2014-08-11 | 2019-02-05 | Albany Medical College | Myristoylated leptin-related peptides and uses thereof |
KR102569743B1 (ko) | 2014-10-06 | 2023-08-23 | 케이스 웨스턴 리저브 유니버시티 | 이상 단일 사슬 인슐린 유사체 |
SI3229828T1 (sl) | 2014-12-12 | 2023-06-30 | Sanofi-Aventis Deutschland Gmbh | Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid |
CN105884879A (zh) * | 2015-01-26 | 2016-08-24 | 漳州博欣生物技术有限公司 | 一种胰岛素类似物的化学合成方法 |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
AR106364A1 (es) * | 2015-08-25 | 2018-01-10 | Novo Nordisk As | Derivados de insulina y sus usos médicos |
CN105597087B (zh) * | 2016-01-06 | 2019-04-26 | 山东新时代药业有限公司 | 一种甘精胰岛素注射液及其制备方法 |
BR112019004314A2 (pt) | 2016-09-06 | 2019-05-28 | Chemical & Biopharmaceutical Laboratories Of Patras S A | derivados pró-insulina |
AU2017373651B2 (en) | 2016-12-05 | 2022-03-10 | Nuritas Limited | Compositions comprising peptide wkdeagkplvk |
EP3329930A1 (en) | 2016-12-05 | 2018-06-06 | Nuritas Limited | Pharmaceuctical compositions |
BR112019011761A2 (pt) | 2016-12-16 | 2019-11-05 | Novo Nordisk As | composições farmacêuticas contendo insulina |
WO2018200462A1 (en) * | 2017-04-24 | 2018-11-01 | Friedman Simon H | Drug conjugates with photocleavable solubility modulators |
JOP20190273A1 (ar) * | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
WO2019125878A1 (en) | 2017-12-18 | 2019-06-27 | Merck Sharp & Dohme Corp. | Conjugate based systems for controlled insulin delivery |
EP3740212A4 (en) | 2017-12-18 | 2021-10-27 | Merck Sharp & Dohme Corp. | CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY |
WO2019222221A1 (en) * | 2018-05-14 | 2019-11-21 | Dance Biopharm Inc. | Insulin formulations for reconstitution into high concentration liquid solutions |
US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
KR20210102347A (ko) | 2018-12-11 | 2021-08-19 | 사노피 | 인슐린 수용체 결합 친화성이 감소된 인슐린 유사체 |
CN110063932A (zh) * | 2019-04-12 | 2019-07-30 | 浙江大学 | 一种多肽蛋白类药物的缓释组合物制剂及其制备方法 |
US11498951B2 (en) | 2019-12-11 | 2022-11-15 | Novo Nordisk A/S | Insulin analogues and uses thereof |
CR20220555A (es) | 2020-03-31 | 2023-01-23 | Protomer Tech Inc | Conjugados para reactividad selectiva a dioles vecinales |
AU2021273262A1 (en) | 2020-05-15 | 2022-12-08 | Eli Lilly And Company | Extended time action acylated insulin compounds |
PE20231948A1 (es) | 2020-11-19 | 2023-12-05 | Protomer Tech Inc | Compuestos aromaticos que contienen boro y analogos de insulina |
WO2022125587A1 (en) * | 2020-12-07 | 2022-06-16 | Case Western Reserve University | Acylated single-chain insulin analogues |
WO2023225534A1 (en) | 2022-05-18 | 2023-11-23 | Protomer Technologies Inc. | Aromatic boron-containing compounds and related insulin analogs |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2538018A (en) | 1944-04-04 | 1951-01-16 | Nordisk Insulinlab | Crystalline product of insulin and alkaline protein and process of making it |
US2801953A (en) | 1952-02-28 | 1957-08-06 | Hoechst Ag | Process of preparing crystallized insulin preparations |
US2849370A (en) | 1953-06-04 | 1958-08-26 | Novo Terapeutisk Labortorium A | Injectable insulin preparations with protracted effect and process of producing same |
US3102077A (en) | 1953-08-19 | 1963-08-27 | Christensen Henry Marinus | Preparation of insulin containing 2.75 to 8 percent zinc content |
US3060093A (en) | 1957-07-18 | 1962-10-23 | Nordisk Insulinlab | Slowly acting insulin preparation in crystalline form and method of preparation |
DE1793517C3 (de) | 1968-09-28 | 1974-12-05 | Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt | N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung |
US3869437A (en) | 1970-05-08 | 1975-03-04 | Nat Res Dev | Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin |
US3950517A (en) | 1970-05-08 | 1976-04-13 | National Research Development Corporation | Insulin derivatives |
GB1381274A (en) | 1971-01-28 | 1975-01-22 | Nat Res Dev | Insulin derivatives |
US3868358A (en) | 1971-04-30 | 1975-02-25 | Lilly Co Eli | Protamine-insulin product |
US3865325A (en) | 1971-07-02 | 1975-02-11 | Dylaker Computer Systems Inc | Flexible tape reel |
US3907763A (en) | 1972-03-01 | 1975-09-23 | Bayer Ag | Insulin derivatives crosslinked by a dicarboxylic acid moiety |
US4183849A (en) | 1975-01-15 | 1980-01-15 | Nordisk Insulinlaboratorium | Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect |
JPS55138393A (en) | 1979-04-13 | 1980-10-29 | Shionogi & Co Ltd | Semisynthesis of insulin |
JPS55138391A (en) | 1979-04-13 | 1980-10-29 | Shionogi & Co Ltd | New synthetic method of peptide derivative |
IE50892B1 (en) | 1980-02-11 | 1986-08-06 | Novo Industri As | Process for preparing insulin esters |
DE3101382A1 (de) | 1981-01-17 | 1982-09-02 | Hoechst Ag, 6000 Frankfurt | "verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten" |
EP0088117B1 (en) | 1981-09-15 | 1986-09-24 | Nordisk Insulinlaboratorium | Process for preparing human insulin or b-30 esters thereof |
DK353781A (da) | 1981-08-10 | 1983-02-11 | Novo Industri As | Fremgangsmaade til fremstilling af insulinderivater |
DE3326473A1 (de) | 1983-07-22 | 1985-01-31 | Hoechst Ag, 6230 Frankfurt | Pharmazeutisches mittel zur behandlung des diabetes mellitus |
DE3327709A1 (de) * | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung |
US4946828A (en) * | 1985-03-12 | 1990-08-07 | Novo Nordisk A/S | Novel insulin peptides |
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
JPH03506023A (ja) | 1988-07-20 | 1991-12-26 | ノボ ノルデイスク アクツイエセルスカプ | ポリペプチド |
DE3837825A1 (de) * | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
HUT56857A (en) | 1988-12-23 | 1991-10-28 | Novo Nordisk As | Human insulin analogues |
US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
DK134189D0 (da) | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | Insulinforbindelser |
DK72793D0 (da) | 1993-06-21 | 1993-06-21 | Novo Nordisk As | Nyt produkt |
DK0705275T3 (da) | 1993-06-21 | 1999-09-20 | Novo Nordisk As | AspB28-insulin-krystaller |
WO1995007931A1 (en) * | 1993-09-17 | 1995-03-23 | Novo Nordisk A/S | Acylated insulin |
US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
US5461031A (en) * | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
US5597893A (en) | 1994-10-31 | 1997-01-28 | Eli Lilly And Company | Preparation of stable insulin analog crystals |
US5646242A (en) * | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
US5693609A (en) * | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
AU720966B2 (en) | 1995-03-17 | 2000-06-22 | Novo Nordisk A/S | Insulin derivatives |
US5700904A (en) * | 1995-06-07 | 1997-12-23 | Eli Lilly And Company | Preparation of an acylated protein powder |
US5877153A (en) | 1996-06-11 | 1999-03-02 | Commonwealth Biotechnologies Inc. | Heparin-binding peptides |
US5948751A (en) | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
EP0910402B1 (en) | 1996-06-20 | 2007-08-08 | Novo Nordisk A/S | Insulin preparations containing mannitol |
ATE294189T1 (de) | 1997-02-07 | 2005-05-15 | Novo Nordisk As | Kristallisation von proteinen |
ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
-
1998
- 1998-10-22 BR BR9813111-7A patent/BR9813111A/pt not_active IP Right Cessation
- 1998-10-22 ID IDW20000748A patent/ID24890A/id unknown
- 1998-10-22 CA CA002306877A patent/CA2306877A1/en not_active Abandoned
- 1998-10-22 AU AU11117/99A patent/AU1111799A/en not_active Abandoned
- 1998-10-22 EA EA200000453A patent/EA200000453A1/ru unknown
- 1998-10-22 KR KR1020007004395A patent/KR20010024556A/ko not_active Application Discontinuation
- 1998-10-22 HU HU0004169A patent/HUP0004169A3/hu unknown
- 1998-10-22 JP JP2000517731A patent/JP2001521004A/ja not_active Withdrawn
- 1998-10-22 WO PCT/US1998/022313 patent/WO1999021573A1/en not_active Application Discontinuation
- 1998-10-22 CO CO98061475A patent/CO4970769A1/es unknown
- 1998-10-22 IL IL13490198A patent/IL134901A0/xx unknown
- 1998-10-22 PE PE1998000996A patent/PE123799A1/es not_active Application Discontinuation
- 1998-10-22 CA CA002306905A patent/CA2306905A1/en not_active Abandoned
- 1998-10-22 US US09/177,685 patent/US6268335B1/en not_active Expired - Lifetime
- 1998-10-22 AR ARP980105267A patent/AR020047A1/es unknown
- 1998-10-22 AU AU11166/99A patent/AU747926B2/en not_active Ceased
- 1998-10-22 EP EP98953852A patent/EP1039920A4/en not_active Withdrawn
- 1998-10-22 SV SV1998000125A patent/SV1998000125A/es unknown
- 1998-10-22 PL PL98340255A patent/PL340255A1/xx not_active Application Discontinuation
- 1998-10-22 WO PCT/US1998/022434 patent/WO1999021578A1/en not_active Application Discontinuation
- 1998-10-22 CN CN98810334A patent/CN1276731A/zh active Pending
- 1998-10-22 JP JP2000517736A patent/JP2001521006A/ja not_active Withdrawn
- 1998-10-22 TR TR2000/01050T patent/TR200001050T2/xx unknown
-
2000
- 2000-04-18 NO NO20002038A patent/NO20002038L/no not_active Application Discontinuation
- 2000-04-21 HR HR20000236A patent/HRP20000236A2/hr not_active Application Discontinuation
-
2001
- 2001-01-17 US US09/761,903 patent/US6465426B2/en not_active Expired - Fee Related
- 2001-12-06 US US10/010,038 patent/US20020082199A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20002038D0 (no) | 2000-04-18 |
US20010036916A1 (en) | 2001-11-01 |
HUP0004169A2 (hu) | 2001-05-28 |
EP1039920A1 (en) | 2000-10-04 |
EP1039920A4 (en) | 2003-05-28 |
ID24890A (id) | 2000-08-31 |
CO4970769A1 (es) | 2000-11-07 |
PE123799A1 (es) | 1999-12-13 |
IL134901A0 (en) | 2001-05-20 |
AR020047A1 (es) | 2002-04-10 |
JP2001521004A (ja) | 2001-11-06 |
TR200001050T2 (tr) | 2000-08-21 |
EA200000453A1 (ru) | 2000-10-30 |
KR20010024556A (ko) | 2001-03-26 |
JP2001521006A (ja) | 2001-11-06 |
SV1998000125A (es) | 1999-05-24 |
AU747926B2 (en) | 2002-05-30 |
HRP20000236A2 (en) | 2001-02-28 |
US6268335B1 (en) | 2001-07-31 |
US6465426B2 (en) | 2002-10-15 |
WO1999021578A1 (en) | 1999-05-06 |
US20020082199A1 (en) | 2002-06-27 |
BR9813111A (pt) | 2000-08-15 |
AU1111799A (en) | 1999-05-17 |
CN1276731A (zh) | 2000-12-13 |
NO20002038L (no) | 2000-06-26 |
WO1999021573A1 (en) | 1999-05-06 |
CA2306905A1 (en) | 1999-05-06 |
AU1116699A (en) | 1999-05-17 |
CA2306877A1 (en) | 1999-05-06 |
PL340255A1 (en) | 2001-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0004169A3 (en) | Insoluble insulin compositions and process for production thereof | |
IL127057A0 (en) | Epichlorohydrin-based product and process for manufacturing this product | |
HUP9800208A3 (en) | Omega-cycloalkyl-prostaglandin e2-derivatives and process for preparing them | |
IL131298A0 (en) | A pharmaceutical composition and a process for producing the same | |
HUP0002877A3 (en) | Stable insulin formulations and process for their preparation | |
HUP0100431A3 (en) | Adamantana derivatives, pharmaceutical compositions comprising them and process for preparing them | |
HUT70848A (en) | 1-aminoethyl-indol derivatives, process for production thereof and pharmaceutical compositions comprising them | |
HUP0004419A3 (en) | Novel aryloxy-alkyl-dialkylamines and process for producing them | |
HUP0002248A3 (en) | Tablets, and process for making tablets | |
HUP0100488A3 (en) | Thienopyrimidines, process for their preparation and pharmaceutical compositions containing them | |
HUP0001522A3 (en) | Benzoimidazole derivatives, process for producing them and pharmaceutical compositions containing them | |
HU9802180D0 (en) | Process for producing pharmaceutical compositions | |
EP0953674A4 (en) | NUBUCK TYPE SIMILICATOR AND MANUFACTURING METHOD THEREOF | |
HUP0003823A2 (en) | Cyanoguanidines process for producing them and pharmaceutical compositions containing them | |
HUP9700989A3 (en) | Ortho-substituted benzoyl-guanidines, process for producing them, and pharmaceutical compositions containing them | |
HUP0003766A2 (en) | Isoguinolin derivatives, process for producing them and pharmaceutical compositions containing them | |
HUP9601331A3 (en) | Piperazine- and homopiperazine-derivatives, process for producing them and pharmaceutical compositions containing them | |
HK1033171A1 (en) | Process for obtaining l-dihydroorotic acid and usethereof | |
HUP0003997A3 (en) | 3-benzylpiperidine derivatives, pharmaceutical compositions containing them and process for producing them | |
GB9819651D0 (en) | Matrerial and process for its production | |
HUP9904592A3 (en) | 1,2-dithiolane-derivatives, process for their production and medicaments containing them | |
HUP0004177A3 (en) | 4,5-diaryloxazole derivatives, pharmaceutical compositions containing them and process for producing them | |
HUP0004132A3 (en) | Rapidly soluble drug composition | |
SG78300A1 (en) | Production process | |
HK1026703A1 (en) | Novel substance ft-0554 and process for producing the same |